- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02061631
Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck (DECIDE)
Open Label, Non Controlled, Non Randomized, Interventional Study to Evaluate the Response Rate After Induction Therapy With DocEtaxel and CIsplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of heaD and nEck
Primary Objective:
To evaluate the overall response rate (including complete response and partial response) of subjects treated with combination therapy docetaxel and cisplatin followed by the chemoradiotherapy in patients with locally advanced head and neck cancer
Secondary Objective:
To assess the safety and tolerability of combination therapy docetaxel and cisplatin followed by the chemoradiotherapy in patients with locally advanced head and neck cancer
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Pakistan, Pakistan
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria :
- Histologically confirmed, unresectable locally advanced squamous cell carcinoma of head and neck of oral cavity in stage III-IV without evidence of distant metastases.
- No prior chemotherapy or radiation therapy.
- Having at least one measurable lesion in one dimension.
- Age ≥18 and <65 years with Eastern Cooperative Oncology Group ≤ 1.
- Adequate organ function:
- Adequate hematological function
- Adequate hepatic function
- Renal function within normal limits
Exclusion criteria:
- Peripheral neuropathy > grade 1 or other serious diseases (unstable ischaemic heart disease, acute myocardial infarction six months prior to inclusion, history of significant neurological or psychiatric disorder or active peptic ulcer).
- Being treated concomitantly with corticosteroids (except as pre-medication).
- Patients having another type of cancer.
- Previous chemotherapy or radiotherapy.
- Any previous definitive surgery for squamous cell carcinoma of head and neck.
- Severe weight loss (> 20 % of body weight) in the preceding 3 months.
- Hearing loss (> grade 2).
- Pregnancy (pregnancy test result for women of childbearing potential).
- Sexually active females with lack of adequate contraception.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Docetaxel, Cisplatin
Induction:One-hour intravenous infusion of docetaxel at 75 mg/m2 followed by a 30 minute intravenous infusion of cisplatin at 75 mg/m2. All patients to be pre-medicated with oral dexamethasone at 8 mg twice daily for 3 days, commencing one day before docetaxel infusion. All patients will be premedicated with intravenous dexamethasone 20 mg to be administered before cisplatin infusion. Docetaxel and cisplatin treatments to be repeated every 21 days for three cycles. Chemoradiotherapy (CRT): Cisplatin to be administered by 30 minutes intravenous infusion at a dose of 30 mg/m2 weekly starting concomitantly with conventional radiotherapy for a period of 6 weeks. Intravenous cisplatin to be continued for four weeks. Radiotherapy: Gross disease dose will be 60 Gy/30 fractions and sub clinical dose 45-50 Gy/30 fractions. |
Pharmaceutical form:solution Route of administration: intravenous
Pharmaceutical form:solution Route of administration: intravenous
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:solution Route of administration: intravenous
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Proportion of patients who achieve complete response and partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: Day 21 after cycle 3
|
Day 21 after cycle 3
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Proportion of patients who achieve complete response and partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: 8 weeks after end of chemoradiotherapy
|
8 weeks after end of chemoradiotherapy
|
Number of patients with Adverse Events (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade)
Lasso di tempo: From Day 1 cycle 1 up to Day 1 chemoradiotherapy or 30 days after the last cycle of induction therapy, whichever comes first
|
From Day 1 cycle 1 up to Day 1 chemoradiotherapy or 30 days after the last cycle of induction therapy, whichever comes first
|
Number of patients with Adverse Events (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade)
Lasso di tempo: From Day 1 chemoradiotherapy up to or 30 days after the last day of radiotherapy
|
From Day 1 chemoradiotherapy up to or 30 days after the last day of radiotherapy
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie per sede
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie della testa e del collo
- Neoplasie, cellule squamose
- Carcinoma
- Carcinoma, cellule squamose
- Carcinoma a cellule squamose della testa e del collo
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti autonomi
- Agenti del sistema nervoso periferico
- Inibitori enzimatici
- Agenti antinfiammatori
- Agenti antineoplastici
- Modulatori della tubulina
- Agenti antimitotici
- Modulatori della mitosi
- Antiemetici
- Agenti gastrointestinali
- Glucocorticoidi
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Agenti antineoplastici, ormonali
- Inibitori della proteasi
- Docetaxel
- Desametasone
- Desametasone acetato
- BB 1101
- Cisplatino
Altri numeri di identificazione dello studio
- DOCETL06445
- U1111-1131-0614 (Altro identificatore: UTN)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cisplatin
-
Korea Cancer Center HospitalCompletatoNEOPLASMI CERVICALICorea, Repubblica di
-
Ruhr University of BochumCompletatoCancro ovarico ricorrenteGermania